Novavax Investor Relations https://ir.novavax.com/ Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study https://novavax.investorroom.com/press-releases?item=610 <p>Sanofi presented positive results from COMPARE, the first head-to-head, double-blind, randomized Phase 4 study powered to directly compare the tolerability profiles of Novavax&rsquo;s protein-based non-mRNA COVID-19 vaccine Nuvaxovid&trade; and mNEXSPIKE, Moderna&#39;s latest mRNA COVID-19 vaccine. The study showed that Nuvaxovid demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE across all pre-specified endpoints.</p> 04/18/2026 https://novavax.investorroom.com/press-releases?item=610 Novavax Announces Entering into a License Agreement with Pfizer https://novavax.investorroom.com/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer <p>Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the...</p> 01/20/2026 https://novavax.investorroom.com/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP  https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP <p>Introductory Remarks for Nuvaxovid at September 2025 Advisory Committee on Immunization Practices (ACIP) Meeting</p> 09/19/2025 https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP